Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Astellas Pharama Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to a single distinct examiner, CARTER, SANDRA DILLAHUNT, who is also the busiest examiner for the portfolio with 1 pending case. The prosecution activity is concentrated within 1 distinct art unit, reflecting a focused point of contact for the company's current patent efforts. This concentration suggests that the portfolio's immediate needs are localized rather than distributed across various USPTO divisions.
For practitioners, this data indicates a streamlined interaction with the USPTO. Because there is only 1 pending office action and 1 distinct examiner involved, the company does not face the complexity of managing multiple examiner styles or conflicting art unit requirements. CARTER, SANDRA DILLAHUNT, handles the entirety of the 1 pending case, making this examiner the primary focus for any immediate prosecution strategy. The presence of only 1 distinct art unit further simplifies the administrative oversight required for these Biotechnology & Pharmaceuticals filings, as there are no competing art unit norms to navigate.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +28.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19222730 | STING AGONIST IMMUNOSTIMULATORY ANTIBODY DRUG CONJUGATES | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19222730 | STING AGONIST IMMUNOSTIMULATORY ANTIBODY DRUG CONJUGATES | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | — | Pending | May 29, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstellas Pharama Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sandra Dillahunt Carter has the most, with 1 of Astellas Pharama Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
